Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron), 100 µg  

Recombinant SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron), 100 µg

Recombinant SARS-CoV-2 Nucleocapsid protein, (BA.3*(S33V)/Omicron), AA Met 1 - Ala 419, expressed from human 293 cells, His Tag

Synonyms: Recombinant, SNucleocapsid protein, NP, Protein N

More details

NUN-C52Hv-100

Availability: within 10-14 days

520,00 €

Background
Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.

Source
Recombinant SARS-CoV-2 Nucleocapsid protein, His Tag (BA.3*(S33V)/Omicron) (NUN-C52Hv) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 419 (Accession # QHO62115.1(P13L, GER 30-32del, S33V, R203K, G204R, S413R)). The mutations (P13L, GER 30-32del, S33V, R203K, G204R, S413R) were identified in the SARS-CoV-2 Omicron variant (Pango lineage: BA.3; GISAID clade: GRA; Nextstrain clade: 21M).
Predicted N-terminus: Met 1

This product is an infrequent version of BA.3 nucleocapsid protein from GISAID. For a common version, please check NUN-C52Hu.

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 47.1 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.2M Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) Preparation and pre-clinical evaluation of flagellin-adjuvanted NOM vaccine candidate formulated with Spike protein against SARS-CoV-2 in mouse model
Farshidi, Farshidi, Ghaedi et al
Microb Pathog (2022)
(2) "Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka
Hoshida, Koeda, Hattori et al
BMC Infect Dis (2022) 22 (1), 709
(3) "Exosomes from WSSV-infected shrimp contain viral components that mediate virus infection
Sun, Zhang
J Gen Virol (2022) 103 (8)
Showing 1-3 of 52963 papers.